Floatz logo

Favezelimab

Colorectal Cancer

Merck Sharp & Dohme LLCmonoclonal_antibodyPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
59/ 100

Competitive context

839 Active assets in the Colorectal Cancer cohort.

Asset / SponsorPhaseRating
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
MARBLE DUST
James Varani
Phase 2/3BB
PANITUMUMAB
M.D. Anderson Cancer Center
Phase 3BB
FLUOROURACILUM
Washington University School of Medicine
Phase 4BB
Cetuximab
Shanghai Henlius Biotech
Phase 4BB

View all 50 →

Same molecule, other indications

Favezelimab is also rated in:

Hodgkins lymphomaDormant
BB
Indicative ·
67 / 100
View asset →
neoplasmDormant
B
Indicative ·
60 / 100
View asset →
skin squamous cell carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →